Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2013
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical modelsYmera Pignochino, Carmine Dell'Aglio, Marco Basiricò, et al.
Cells|November 4, 2020
High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective SeriesEmanuela Palmerini, Elisabetta Setola, Giovanni Grignani, et al.
Cancers|December 24, 2021
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational StudyYmera Pignochino, Giovanni Crisafulli, Giorgia Giordano, et al.
ACS Medicinal Chemistry Letters|August 14, 2024
AI Based Discovery of a New AKR1C3 Inhibitor for Anticancer ApplicationsAgnese C Pippione, Chiara Vigato, Cristina Tucciarello, et al.
The Lancet. Oncology|December 16, 2014
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trialGiovanni Grignani, Emanuela Palmerini, Virginia Ferraresi, et al.
BMC Cancer|May 9, 2015
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesotheliomaYmera Pignochino, Carmine Dell'Aglio, Simona Inghilleri, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 16, 2012
Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriersMaja Todorovic, Giulia Mesiano, Loretta Gammaitoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2013
Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness featuresLoretta Gammaitoni, Lidia Giraudo, Valeria Leuci, et al.
Cancer Immunology, Immunotherapy : CII|September 23, 2025
The cGAS-STING pathway is a master regulator of OCT4 expression in persistent sarcoma cells and enhances cellular immunotherapy with NK and CIK lymphocytesGiorgia Giordano, Alessandra Merlini, Federica Capozzi, et al.
Cancers|June 14, 2020
Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular InsightsGiulia Chiabotto, Giovanni Grignani, Maja Todorovic, et al.
Pageof 6